These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 9792818)

  • 1. A hammerhead ribozyme targeted to the human chemokine receptor CCR5.
    González MA; Serrano F; Llorente M; Abad JL; García-Ortiz MJ; Bernad A
    Biochem Biophys Res Commun; 1998 Oct; 251(2):592-6. PubMed ID: 9792818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Downregulation of the CCR5 beta-chemokine receptor and inhibition of HIV-1 infection by stable VA1-ribozyme chimeric transcripts.
    Cagnon L; Rossi JJ
    Antisense Nucleic Acid Drug Dev; 2000 Aug; 10(4):251-61. PubMed ID: 10984119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of CCR5-dependent HIV-1 infection by hairpin ribozyme gene therapy against CC-chemokine receptor 5.
    Feng Y; Leavitt M; Tritz R; Duarte E; Kang D; Mamounas M; Gilles P; Wong-Staal F; Kennedy S; Merson J; Yu M; Barber JR
    Virology; 2000 Oct; 276(2):271-8. PubMed ID: 11040119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multivalent anti-CCR ribozymes for stem cell-based HIV type 1 gene therapy.
    Bai J; Rossi J; Akkina R
    AIDS Res Hum Retroviruses; 2001 Mar; 17(5):385-99. PubMed ID: 11282007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequence specific cleavage of the HIV-1 coreceptor CCR5 gene by a hammer-head ribozyme and a DNA-enzyme: inhibition of the coreceptor function by DNA-enzyme.
    Goila R; Banerjea AC
    FEBS Lett; 1998 Oct; 436(2):233-8. PubMed ID: 9781685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo.
    Bai J; Gorantla S; Banda N; Cagnon L; Rossi J; Akkina R
    Mol Ther; 2000 Mar; 1(3):244-54. PubMed ID: 10933940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA.
    Sun LQ; Wang L; Gerlach WL; Symonds G
    Nucleic Acids Res; 1995 Aug; 23(15):2909-13. PubMed ID: 7544887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of human immunodeficiency virus-1 entry using vectors expressing a multimeric hammerhead ribozyme targeting the CCR5 mRNA.
    Nazari R; Ma XZ; Joshi S
    J Gen Virol; 2008 Sep; 89(Pt 9):2252-2261. PubMed ID: 18753234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hammerhead ribozymes targeted to the FBN1 mRNA can discriminate a single base mismatch between ribozyme and target.
    Phylactou LA; Tsipouras P; Kilpatrick MW
    Biochem Biophys Res Commun; 1998 Aug; 249(3):804-10. PubMed ID: 9731217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene silencing of HIV chemokine receptors using ribozymes and single-stranded antisense RNA.
    Qureshi A; Zheng R; Parlett T; Shi X; Balaraman P; Cheloufi S; Murphy B; Guntermann C; Eagles P
    Biochem J; 2006 Mar; 394(Pt 2):511-8. PubMed ID: 16293105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protecting from R5-tropic HIV: individual and combined effectiveness of a hammerhead ribozyme and a single-chain Fv antibody that targets CCR5.
    Cordelier P; Kulkowsky JW; Ko C; Matskevitch AA; McKee HJ; Rossi JJ; Bouhamdan M; Pomerantz RJ; Kari G; Strayer DS
    Gene Ther; 2004 Nov; 11(22):1627-37. PubMed ID: 15295615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multifunctional expression vector for an anti-HIV-1 ribozyme that produces a 5'- and 3'-trimmed trans-acting ribozyme, targeted against HIV-1 RNA, and cis-acting ribozymes that are designed to bind to and thereby sequester trans-activator proteins such as Tat and Rev.
    Yuyama N; Ohkawa J; Koguma T; Shirai M; Taira K
    Nucleic Acids Res; 1994 Nov; 22(23):5060-7. PubMed ID: 7800500
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The 5'-end of hTERT mRNA is a good target for hammerhead ribozyme to suppress telomerase activity.
    Yokoyama Y; Takahashi Y; Shinohara A; Wan X; Takahashi S; Niwa K; Tamaya T
    Biochem Biophys Res Commun; 2000 Jun; 273(1):316-21. PubMed ID: 10873604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted cleavage of HIV-1 coreceptor-CXCR-4 by RNA-cleaving DNA-enzyme: inhibition of coreceptor function.
    Basu S; Sriram B; Goila R; Banerjea AC
    Antiviral Res; 2000 May; 46(2):125-34. PubMed ID: 10854664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a hammerhead ribozyme against bcl-2. I. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer.
    Dorai T; Olsson CA; Katz AE; Buttyan R
    Prostate; 1997 Sep; 32(4):246-58. PubMed ID: 9288183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Examination of the catalytic fitness of the hammerhead ribozyme by in vitro selection.
    Tang J; Breaker RR
    RNA; 1997 Aug; 3(8):914-25. PubMed ID: 9257650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 LTR as a target for synthetic ribozyme-mediated inhibition of gene expression: site selection and inhibition in cell culture.
    Bramlage B; Luzi E; Eckstein F
    Nucleic Acids Res; 2000 Nov; 28(21):4059-67. PubMed ID: 11058100
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A three-nucleotide helix I is sufficient for full activity of a hammerhead ribozyme: advantages of an asymmetric design.
    Tabler M; Homann M; Tzortzakaki S; Sczakiel G
    Nucleic Acids Res; 1994 Sep; 22(19):3958-65. PubMed ID: 7937118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of variations in length of hammerhead ribozyme antisense arms upon the cleavage of longer RNA substrates.
    Sioud M
    Nucleic Acids Res; 1997 Jan; 25(2):333-8. PubMed ID: 9016562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attenuation of telomerase activity by hammerhead ribozymes targeting human telomerase RNA and telomerase reverse transcriptase in pancreatic carcinoma cells.
    Hayashidani Y; Hiyama E; Murakami Y; Sueda T
    Hiroshima J Med Sci; 2005 Mar; 54(1):21-7. PubMed ID: 15847061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.